Back to Authors

Rotbain, Emelie Curovic

https://orcid.org/0000-0002-4199-772X

Mayo Clinic

Rigshospitalet

Citations 4

Comparison of Frontline Therapies in Older Adults Age ≥ 80 Years With Chronic Lymphocytic Leukemia (CLL): A Mayo Clinic and Danish Nation‐Wide Study
Tsang, Mazie , Hampel, Paul J. , Rabe, Kari G. , Ding, Wei , Leis, José F., Kenderian, Saad S. , Wang, Yucai , Muchtar, Eli , Koehler, Amber B. , Dyke, Daniel L. Van , Hanson, Curtis A. , Hjalgrim, Henrik , Ding, Wei , Kenderian, Saad Sirop , Wang, Yucai , Muchtar, E , Van Dyke, Daniel L, Shi, Min , Parikh, Sameer A , Chaffee, Kari G. , Tsang, Mazie , Brieghel, Christian , Hilal, Talal , Slager, Susan L. , Kay, Neil E. , Niemann, Carsten Utoft , Parikh, Sameer A. , Rotbain, Emelie Curovic

American Journal of Hematology | June 29, 2025 | Volume: 100 | Issue: 9 | Pages: 1678-1681

10.1002/ajh.27747 Get It

Understanding the interplay between chronic lymphocytic leukemia and type 2 diabetes
Vainer, Noomi , Curovic, Viktor Rotbain , Niemann, Carsten Utoft , Slager, Susan L. , Rotbain, Emelie Curovic

Expert Review of Hematology | July 23, 2024 | Volume: 17 | Issue: 9 | Pages: 617-629

10.1080/17474086.2024.2383417 Get It

Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia
Rotbain, Emelie Curovic , Allmer, Cristine, Rostgaard, Klaus , Andersen, Michael Asger , Vainer, Noomi , Parikh, Sameer A. , Rabe, Kari G. , Hjalgrim, Henrik , Frederiksen, Henrik , Niemann, Carsten Utoft , Parikh, Sameer A , Chaffee, Kari G. , Frederiksen, Henrik , Cunha‐Bang, Caspar da , Slager, Susan L.

American Journal of Hematology | May 22, 2023 | Volume: 98 | Issue: 8 | Pages: 1236-1245

10.1002/ajh.26964 Get It

AbstractAge‐related comorbid conditions are exceedingly common in patients with chronic lymphocytic leukemia (CLL). As the prevalence of type 2 diabetes (T2D) is predicted to double during the next two decades, a better understanding of the interplay between CLL and T2D is of increasing importance. In this study, analyses were performed in parallel in two separate cohorts, based on Danish national registers and the Mayo Clinic CLL Resource. The primary outcomes were overall survival (OS) from time of CLL diagnosis, OS from time of treatment, and time to first treatment (TTFT), studied using Cox proportional hazard regression analysis and Fine‐Gray regression analysis. In the Danish CLL cohort, the prevalence of T2D was 11%, in the Mayo CLL cohort, it was 12%. Patients with CLL and T2D had shorter OS both from time of diagnosis and from first‐line treatment for were less likely to receive treatment for CLL compared with patients with CLL and without T2D. The increased mortality was largely driven by an increased risk of death due to infections, especially in the Danish cohort. The findings of this study emphasize a substantial subgroup of CLL patients with co‐occurring T2D with an inferior prognosis and a possible unmet treatment need requiring additional interventions and further research.
P642: IMPACT OF TYPE 2 DIABETES ON SURVIVAL AND TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Andersen, Michael Asger , Vainer, Noomi , Hjalgrim, Henrik , Frederiksen, Henrik , Frederiksen, Henrik , Rotbain, Emelie Curovic , Rostgaard, Klaus , Cunha‐Bang, Caspar da , Slager, Susan L. , Niemann, Carsten Utoft

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 540-541

10.1097/01.hs9.0000845452.89743.80 Get It